KTI-m218

KTI-m218 is an orally bioavailable, small-molecule dual inhibitor of the mechanistic target of rapamycin (mTOR) complexes 1 and 2 (mTORC1 and mTORC2). Developed by Karyopharm Therapeutics, it functions as an ATP-competitive inhibitor of the mTOR kinase domain. Unlike first-generation mTOR inhibitors such as rapamycin and its analogs (rapalogs), which primarily target mTORC1, KTI-m218 inhibits both complexes, thereby preventing the compensatory activation of AKT that often occurs when mTORC1 is inhibited in isolation. Preclinical data suggests that KTI-m218 effectively suppresses the PI3K/AKT/mTOR signaling pathway, leading to inhibited cell proliferation and induced apoptosis in various cancer cell lines, including those of solid tumors and hematological malignancies.